Taiwan's Food and Drug Administration investigated magnesium carbonate and calcium carbonate supplied by Yuncheng and Yixing and found 23 products from 13 of 27 drug makers were made with food-grade or food-additive raw materials instead of pharmaceutical grade. Samples of the magnesium carbonate failed pharmacopoeia standards for arsenic, iron, calcium oxide and assay, and the FDA has halted sales of the affected inventory.
This is a domestic pharmaceutical raw-material compliance action with no measurable effect on feed grain, protein or mineral supply or prices. It is unlikely to move feed-grade magnesium or calcium carbonate markets.
Not enough comparable past events yet for a historical read.
Moves of each commodity's benchmark from the last close before the event. Historical reads pool past events of the same kind; they describe what happened, not what will. Not investment advice.